Genmab — Februar 2021

[Solsen]

Horizon klarede sig flot i går efter annoncering af M&A

[E_L]

and up even more pre-market today...

[E_L]

i actually only watched their open yesterday, which went below $71 lol, may now open >$85

[E_L]

ah, this may be why, 'Immunovant Announces Voluntary Pause in Clinical Dosing of IMVT-1401' https://www.globenewswire.com/news-release/2021/02/02/2167963/0/en/Immunovant-Announces-Voluntary-Pause-in-Clinical-Dosing-of-IMVT-1401.html#.YBk7ta8wc3k.twitter ; this is a potential Tepezza competitor

[E_L]

omg, Immunovant - 61%.... pre-market

[Mcjean]

Thats a lot are WSB involved?

[E_L]

don't they only buy calls? you should get them to target Genmab, we'll be at your 18000 before the end of the week

[Mcjean]

We could, but we can wait a couple of years just for fun or?

[E_L]

Mcjean, believe me, 18000 this week would be much much more fun

[E_L]

Daratumumab for delayed RBC engraftment following major ABO mismatched haploidentical bone marrow transplantation https://onlinelibrary.wiley.com/doi/abs/10.1111/trf.16281?af=R

[deleted-user]

Imponerende 105.000 aktier omsat i dag.... har der været handelsstop?

[Klarussen]

Folk holder vel på aktierne

[Helge_LarsenPI-redaktør]

God morgen.

[Helge_LarsenPI-redaktør]

Asien: Fremgang overalt - Hongkong undtagethttps://www.proinvestor.com/investornyt/671711/asien-fremgang-overalt-hongkong-undtaget

[Helge_LarsenPI-redaktør]

Onsdagens aviser med Coloplast, Novozymes og Bavarian https://www.proinvestor.com/investornyt/671710/onsdagens-aviser-med-coloplast-novozymes-og-bavarian

[E_L]

Amgen's BCMA Bispecific: AMG 701 Enrollment in the Phase 1 study has been paused while we discuss protocol modifications to optimize safety monitoring and mitigation with the FDA. Currently enrolled patients who are demonstrating benefit may continue to receive investigational product and the Company expects to resume patient enrollment in H1 2021. (Teclistamab rival)

[E_L]

they are also pausing a CD33 bispecific

[E_L]

"Uptake of KYPROLIS in combination with DARZALEX (daratumumab) plus dexamethasone (DKd) in the U.S. has been encouraging as reflected in new patient share, and we expect this momentum to continue into 2021 with additional global regulatory approvals of the DKd combination."

[Klarussen]

Det er godt nok ikke mange Genmab`ber der omsættes de her dage...

[AaBforever]

"Der er så stille nu"...måske stilhed før storm:-)